Yang Cheng

A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects

Xin-Ning Qu, Tianying Chang, Q. Ren, 2022, Expert opinion on investigational drugs.

A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.

Yicheng Zhao, Xin-Ning Qu, Jing Lan, 2022, International immunopharmacology.

A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects

Yicheng Zhao, Zeyu Wang, Lixiu Zhang, 2022, Expert opinion on drug metabolism & toxicology.

Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states

Xin-Ning Qu, Peng Li, Q. Ren, 2022, Frontiers in Pharmacology.

A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects

Yanli Wang, Zeyu Wang, Xin-Ning Qu, 2021, Expert opinion on biological therapy.

Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial

Xin-Ning Qu, Xiuge Wang, Tianying Chang, 2023, Expert review of clinical pharmacology.

Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects

Q. Ren, Yingzi Cui, Guang-ping Liu, 2023, Expert opinion on investigational drugs.